$22,195.53 speaking Payment -- Bayer Healthcare to Dr. Robert Johnson
Ophthalmologist Robert Johnson Receives Over $22,000 for Bayer Healthcare Speaking Engagement
This page provides a detailed analysis of a $22,195.53 speaking payment from Bayer Healthcare to Dr. Robert Johnson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $22,195.53 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Bayer Healthcare |
| Physician | Dr. Robert Johnson |
| NPI Number | 1302859080 |
| Physician Specialty | Ophthalmology |
| Location | City, IN |
| Date of Payment | 2026-01-30 |
| Related Drug/Device | Entresto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bayer Healthcare made a $22.2K speaking payment to Robert Johnson, a Ophthalmology specialist in City, IN. The payment was associated with Entresto. Robert Johnson received $22,195.53 from Bayer Healthcare for speaking engagements in 2026. The payment was for serving as faculty or a speaker, specifically related to Entresto. This payment represents a significant financial interaction between a pharmaceutical company and a physician.
Patient Guidance: What This Payment Means for You
If you are a patient, understand that your doctor may receive compensation for educating others about medications or medical devices. Discuss any concerns about potential conflicts of interest with your physician. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements can be common in many specialties, but the amount and frequency should be considered in the context of typical compensation for similar activities within Ophthalmology.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug and device manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- pharma-payments
- physician-compensation
- bayer-healthcare
- ophthalmology
- entresto
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $22.2K payment for?
This was a speaking payment of $22.2K from Bayer Healthcare to Robert Johnson, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Entresto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Robert Johnson accept pharmaceutical money?
Yes, Robert Johnson received this $22.2K payment from Bayer Healthcare. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Robert Johnson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $22.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Robert Johnson's relationship with Bayer Healthcare?
The payment amount is substantial for a single speaking engagement. This $22.2K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The specific drug mentioned, Entresto, suggests a focus on cardiovascular or related treatments.
What should patients do after learning about this payment?
If you are a patient, understand that your doctor may receive compensation for educating others about medications or medical devices. Discuss any concerns about potential conflicts of interest with your physician.
What else should I know about this speaking payment?
The payment date is in the future, indicating a planned engagement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.